Citadel Advisors
TELO icon

Citadel Advisors’s Telomir Pharmaceuticals TELO Stock Holding History

Citadel Advisors’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17K Buy
+13,266
New +$17.3K ﹤0.01% 13435

Other funds holding TELO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

Citadel Advisors's TELO Position: Q2 2026 in Review

Citadel Advisors opened a new position in Telomir Pharmaceuticals (TELO) in Q2 2026: 13,266 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #13435 among its holdings.

33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

  • Citadel Advisors held 13,266 shares of Telomir Pharmaceuticals worth $17K as of Q2 2026.
  • Telomir Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13435 holding.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.